On November 18, 2021, the Cologne Chamber of Industry and Commerce opened its doors for the event „Transfer – Making it easy“, an information and networking event in which several transfer projects between companies, universities and research institutions were presented. One of our tenants, Singleron Biotechnologies GmbH and one of our network partners, a research team from the University Hospital Cologne, were among the participants.

The Cooperation Partners

Prof. Dr. rer. nat. Margarete Odenthal, head of the Translational Molecular Diagnostics at the the Institute for Pathology which is a center part of the National Genomic Medicine Lung Cancer Network, has published more than 100 articles and four patent applications. Prof. Dr. rer. nat. Margarete Odenthal briefly introduced the importance, and the role that the University Hospital of Cologne with 58 clinics/research institutes, >10,000 employees, is taking, in the overall research.

Prof. Dr. rer. nat. Margarete Odenthal
Dr. Ulla Deutsch

Singleron Biotechnologies GmbH was represented by Dr. Ulla Deutsch. With a Ph.D. in Molecular Biology and the goal of bringing people from different cultures and disciplines together to pursue a common goal and extensive experience in global project management makes her the perfect representative for Singleron Biotechnologies. Founded in 2018 in USA & China in 2021 in Cologne, with more than 400 employees globally – 25 of them in the RTZ, the Rechtsrheinisches Technologie- und Gründerzentrum Köln.

Common Goals

High-throughput single-cell sequencing is a rapidly emerging technology, resulting in unprecedently comprehensive information at both, cellular and molecular levels. Precision medicine, which uses advanced diagnostics methods and tailored to a subgroup of patients, will particularly benefit from the deep insights into the gene expression and genetic level of a heterogeneous sample.

The cooperation has many advantages for both parties. Singleron gains insight into the clinically relevant requirements and can adapt and further develop the technology; in return, the outstanding research team has the direct and earliest contact with the technical innovations. This also enables the discovery of new research approaches, it’s testing and fine adjustment of future-proof technologies, and last but not least: The establishment and initial application of the new technologies provided by Singleron.

A Fundamental Role

The RTZ supports young technology companies in the start-up phase with office space, seminar and meeting rooms and laboratory space, management consulting and a widespread partner and entrepreneurial community of around 70 start-up companies – and the trend is rising. The RTZ is proud to have the fast-growing, innovative, biotechnology company Singleron as a tenant.

RTZ fundamental role